Ruxolitinib cream 鲁索替尼乳膏

Ruxolitinib cream is a topical medication whose main ingredient is a JAK inhibitor. It inhibits the release of inflammatory factors and immune responses. It is used to treat mild to moderate atopic dermatitis (eczema) and non-segmental vitiligo (requires phototherapy) in patients aged 12 years and older. Its effects include relieving skin inflammation, alleviating itching, and helping vitiligo patients regain pigmentation.

I. Core Benefits

Inhibits Inflammatory Response 1.
Overactivation of the JAK-STAT signaling pathway is a key mechanism in diseases such as atopic dermatitis. By blocking this pathway, ruxolitinib reduces the release of proinflammatory cytokines (such as IL-4 and IL-13), thereby alleviating inflammatory symptoms such as redness, swelling, and exudation.

Relieves Itch 2.
Itch is one of the main symptoms of atopic dermatitis. This drug can modulate the immune microenvironment to reduce neurosensitivity, rapidly improving patients’ itch and reducing skin damage caused by scratching.

Promotes Vitiligo Repigmentation 3.
For non-segmental vitiligo, ruxolitinib combined with ultraviolet light therapy can stimulate the proliferation and migration of residual melanocytes, helping to restore skin pigmentation. It is particularly effective for lesions on the face and neck.

II. Indications and Scope of Use
III. Precautions and Safety